ARTHROPLASTY
AAOS: Hemostatic Agent does not appear to reduce transfusion events in THA
109 total hip arthroplasty patients were randomized to receive a collagen/thrombin/autologous platelet hemostatic agent in conjunction with standard hemostasis treatment, or standard hemostasis treatment alone, to determine the efficacy of the hemostatic agent on transfusion events. Other outcome measures included perioperative blood loss and narcotic use, postoperative pain and hemoglobin levels, Short Form (SF-12), and (HOOS) scores. Upon analysis, results indicated no significant difference between groups for any of the aforementioned outcomes except postoperative hemoglobin values, which were consistently higher in the hemostatic agent group on days 1,2, and 3 postoperative.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
